Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke (SPARCL)

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

Official Title

A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke

Conditions

Stroke, Transient Ischemic Attack

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Details

• Primary Outcome Measures: Time to occurrence of fatal or non-fatal stroke
• Secondary Outcome Measures: Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina;Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.

Study Start

November 1998; Study completion: November 2005

Eligibility & Criteria

• Ages Eligible for Study: 18 Years and above
• Genders Eligible for Study: Both
• Inclusion Criteria: Previous stroke or TIA
• Exclusion Criteria: Coronary heart disease

Total Enrolment

4732

Contact Details

Australian Locations:

• Pfizer Investigational Site, RANDWICK, SYDNEY, New South Wales, 2031, Australia
• Pfizer Investigational Site, EAST GOSFORD, New South Wales, 2250, Australia
• Pfizer Investigational Site, Heidelberg Heights, Victoria, 3081, Australia
• Pfizer Investigational Site, PARKVILLE, Victoria, 3050, Australia
• Pfizer Investigational Site, PRAHRAN, Victoria, 3181, Australia
• Pfizer Investigational Site, FOOTSCRAY, Victoria, 3011, Australia
• Pfizer Investigational Site, PERTH, Western Australia, 6000, Australia
• Results of Study
• Results Published at N Engl J Med